Tuberculosis (TB) Clinical Trial
— IQOfficial title:
Assessing the Ability of the T-SPOT®.TB Test to Identify Those at Risk of Active Mycobacterium Tuberculosis Infection Using the Normalized TB Specific Lymphocyte Response
NCT number | NCT03929705 |
Other study ID # | AF SA 148 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | May 2, 2019 |
Est. completion date | January 23, 2020 |
Verified date | July 2020 |
Source | Oxford Immunotec |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The primary objective of this clinical research study is to demonstrate performance of the normalized TB specific lymphocyte response in identifying patients with active TB disease. The secondary exploratory objective is to demonstrate that active TB cannot be identified using an antigen-to-mitogen ratio derived from an ELISA-based IGRA.
Status | Completed |
Enrollment | 676 |
Est. completion date | January 23, 2020 |
Est. primary completion date | January 23, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Cohort 1a and 1b - • Must be at least 18 years of age - Must be able to provide informed consent - Must be able to provide a minimum of 10 mL of whole blood at each visit (16mL for immunocompromised i.e. HIV+) - Must be T-SPOT.TB positive - First visit suspect TB subjects with no prior history of TB diagnosis Inclusion Criteria: Cohort 2a and 2b - Must be at least 18 years of age - Must be able to provide informed consent - Must be able to provide a minimum of 10 mL of whole blood at each visit (16mL for immunocompromised i.e. HIV+) - Must be T-SPOT.TB positive - No prior history of TB diagnosis Exclusion Criteria: Cohort 1a and 1b - • Negative in the T-SPOT.TB test - Previous or pre-existing confirmed TB diagnosis - On anti-TB treatment for more than 1 week* - Not meeting inclusion criteria Exclusion Criteria: Cohort 2a and 2b - Negative T-SPOT.TB test - Previous or pre-existing confirmed TB diagnosis - On anti-TB treatment - Symptoms of active TB - Not meeting inclusion criteria |
Country | Name | City | State |
---|---|---|---|
South Africa | University of Cape Town | Cape Town |
Lead Sponsor | Collaborator |
---|---|
Oxford Immunotec |
South Africa,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | T-Spot | The primary objective of this clinical research study is to demonstrate performance of the normalized TB specific lymphocyte response (NTBSLR) in identifying patients with active TB disease. The secondary exploratory objective is to demonstrate that active TB cannot be identified using an antigen-to-mitogen ratio derived from an ELISA-based IGRA. | 6 month study |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06272812 -
A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in IGRA Positive Adolescents and Adults Living in a TB Endemic Region.
|
Phase 2 | |
Active, not recruiting |
NCT01875952 -
Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection (HIV/TBL)
|
Phase 4 | |
Recruiting |
NCT03808636 -
Innovative Reagents for Improving Rapid Diagnosis of Mycobacterial Infections
|
||
Completed |
NCT01879163 -
Phase I Trial Evaluating Safety and Immunogenicity of MVA85A-IMX313 Compared to MVA85A in BCG Vaccinated Adults
|
Phase 1 | |
Completed |
NCT00146744 -
Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02A in Healthy PPD-positive Adults
|
Phase 2 | |
Completed |
NCT00291889 -
Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02 in Healthy PPD-negative Adults.
|
Phase 1 | |
Recruiting |
NCT04333485 -
Tuberculosis (TB) Aftermath
|
N/A | |
Completed |
NCT00730795 -
Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine Given to PPD-Negative Adults
|
Phase 1 | |
Completed |
NCT00600782 -
Immunogenicity and Safety of a Candidate Tuberculosis (TB) Vaccine Given to Healthy Adults in a TB-endemic Region
|
Phase 2 | |
Withdrawn |
NCT04243031 -
QuantiFERON Access Clinical Performance Study Protocol
|